FDG-PET for evaluating musculoskeletal tumors: a review |
| |
Authors: | Jun Aoki Keigo Endo Hideomi Watanabe Tetsuya Shinozaki Takashi Yanagawa Adel Refaat Ahmed Kenji Takagishi |
| |
Institution: | (1) Department of Diagnostic Radiology, Gunma University School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan, JP;(2) Department of Nuclear Medicine, Gunma University School of Medicine, Maebashi, Japan, JP;(3) Department of Orthopaedic Surgery, Gunma University School of Medicine, Maebashi, Japan, JP |
| |
Abstract: | Positron-emission tomography (PET) can provide an in vivo method for evaluating metabolism and physiology in normal and diseased
tissues. Clinical trials with 18F]2-deoxy-2-fluoro-d-glucose (FDG), the most commonly used radiolabeled tracer for PET imaging, have demonstrated increased accumulation of FDG
in several cancer tissues. In this article, we introduce the basic principles of FDG-PET and review current knowledge about
FDG-PET for evaluating musculoskeletal tumors. Recent reports and our own experience suggest that FDG-PET cannot be a screening
method for differential diagnosis between benign and malignant musculoskeletal lesions, including many neoplasms originating
from different tissues altogether. FDG-PET might not accurately reflect the malignant potential of musculoskeletal tumors,
but rather might implicate cellular components included in the lesions. A high accumulation of FDG can be observed in histiocytic,
fibroblastic, and some neurogenic lesions, regardless of whether they are benign or malignant. More specific uses of FDG-PET,
such as grading, staging, and monitoring of musculoskeletal sarcomas, should be considered for each tumor of a different histologic
subtype.
Received: October 2, 2001
RID="*" |
| |
Keywords: | Bone neoplasms Soft tissue neoplasms Emission CT (ECT) Review |
本文献已被 ScienceDirect SpringerLink 等数据库收录! |
|